{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:17:20Z","timestamp":1762082240707,"version":"build-2065373602"},"reference-count":194,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.amjsurg.2016.06.008","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T13:42:25Z","timestamp":1468935745000},"page":"682-690.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Surgical immune interventions for solid malignancies"],"prefix":"10.1016","volume":"212","author":[{"given":"Masha","family":"Zeltsman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2046","authenticated-orcid":false,"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjsurg.2016.06.008_bib1","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1158\/1078-0432.CCR-10-2805","article-title":"Prognostic immune markers in non-small cell lung cancer","volume":"17","author":"Suzuki","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib2","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib4","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMoa051424","article-title":"Effector memory T cells, early metastasis, and survival in colorectal cancer","volume":"353","author":"Pages","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib7","first-page":"5132","article-title":"Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity","volume":"61","author":"Nakano","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib8","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","article-title":"CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma","volume":"28","author":"Fukunaga","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2012.45.2052","article-title":"Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3\/CD3 ratio are independent predictors of recurrence","volume":"31","author":"Suzuki","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/JTO.0000000000000617","article-title":"Prognostic impact of immune microenvironment in lung squamous cell carcinoma: tumor-infiltrating CD10+ neutrophil\/CD20+ lymphocyte ratio as an independent prognostic factor","volume":"10","author":"Kadota","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib11","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib14","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.4049\/jimmunol.1300538","article-title":"Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy","volume":"191","author":"Turcotte","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib17","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib18","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/thx.35.11.856","article-title":"Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions","volume":"35","author":"Millar","year":"1980","journal-title":"Thorax"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0022-5223(19)38690-8","article-title":"Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group","volume":"89","author":"Kaufmann","year":"1985","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib21","first-page":"1413","article-title":"Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients","volume":"45","author":"Yasumoto","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib22","first-page":"269","article-title":"Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection","volume":"39","author":"Lee","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00199131","article-title":"Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report","volume":"22","author":"Bakker","year":"1986","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib24","first-page":"391","article-title":"Intrapleural BCG in postsurgical stage I non-small cell lung cancer","volume":"9","author":"Macchiarini","year":"1989","journal-title":"Anticancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib25","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","article-title":"Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"83","author":"Astoul","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jgm.877","article-title":"Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses","volume":"8","author":"Adusumilli","year":"2006","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1096\/fj.02-1080fje","article-title":"Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207)","volume":"18","author":"Bennett","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-004-1497-5","article-title":"Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma","volume":"72","author":"Boiardi","year":"2005","journal-title":"J\u00a0Neuro-oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1040-8428(01)00122-6","article-title":"Adoptive cellular immunotherapy for the treatment of malignant gliomas","volume":"39","author":"Hayes","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib30","first-page":"175","article-title":"Intratumoral LAK cell and interleukin-2 therapy of human gliomas","volume":"70","author":"Barba","year":"1989","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib31","first-page":"331","article-title":"Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells","volume":"4","author":"Blancher","year":"1993","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01533386","article-title":"Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients","volume":"39","author":"Boiardi","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib33","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/jnci\/87.19.1463","article-title":"Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody","volume":"87","author":"Canevari","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bjc.1993.349","article-title":"Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody","volume":"68","author":"Hird","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib35","first-page":"746","article-title":"Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy","volume":"36","author":"Kosmas","year":"1995","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib36","first-page":"953","article-title":"Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity","volume":"5","author":"Rosenblum","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib37","first-page":"2806","article-title":"A\u00a0Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer","volume":"8","author":"Alvarez","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib38","first-page":"508","article-title":"Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer","volume":"22","author":"Oei","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0090-8258(92)90302-Y","article-title":"Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125","volume":"45","author":"Muto","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/172460089300800310","article-title":"Radioimmunotherapy of gastrointestinal cancer and glioblastomas","volume":"8","author":"Riva","year":"1993","journal-title":"Int J Biol Markers"},{"issue":"10 Suppl","key":"10.1016\/j.amjsurg.2016.06.008_bib41","first-page":"3249s","article-title":"A\u00a0phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma","volume":"5","author":"Mahe","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"4 Pt 1","key":"10.1016\/j.amjsurg.2016.06.008_bib42","first-page":"586","article-title":"A\u00a0phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response","volume":"82","author":"Jacobs","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/gyno.1996.4577","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I\/II study","volume":"65","author":"Alvarez","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2\u2014a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"3 Suppl","key":"10.1016\/j.amjsurg.2016.06.008_bib45","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/1097-0142(19940201)73:3+<1067::AID-CNCR2820731346>3.0.CO;2-#","article-title":"Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer","volume":"73","author":"Maraveyas","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib46","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib47","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.4161\/hv.26065","article-title":"The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting","volume":"9","author":"Atanackovic","year":"2013","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-14-148","article-title":"Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab","volume":"14","author":"Goere","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib49","first-page":"196","article-title":"Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study","volume":"35","author":"Wright","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib50","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cam4.196","article-title":"Intraperitoneal injection of in\u00a0vitro expanded V\u03b39V\u03b42 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer","volume":"3","author":"Wada","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib51","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","article-title":"Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study","volume":"64","author":"Danielli","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib52","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00262-011-1134-z","article-title":"Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen","volume":"61","author":"Berinstein","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib53","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2005.06.005","article-title":"Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4\/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial","volume":"23","author":"Timar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/hum.2005.16.35","article-title":"Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy","volume":"16","author":"Heinzerling","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.cgt.7701064","article-title":"Intratumoral injection of IL-12 plasmid DNA\u2013results of a phase I\/IB clinical trial","volume":"14","author":"Mahvi","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib56","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/mt.2010.52","article-title":"Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas","volume":"18","author":"Dummer","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib57","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-015-1691-7","article-title":"Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients","volume":"64","author":"Khammari","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma","volume":"64","author":"Aguilar","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01878153","article-title":"The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages","volume":"7","author":"Takeda","year":"1993","journal-title":"Biotherapy"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib61","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/cgt.2009.9","article-title":"Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients","volume":"16","author":"Victora","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib62","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/1097-0142(19821201)50:11<2295::AID-CNCR2820501113>3.0.CO;2-4","article-title":"Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck","volume":"50","author":"Vogl","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib63","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1054\/bjoc.2000.1599","article-title":"The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients","volume":"84","author":"Gochi","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib64","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/1097-0142(19941215)74:12<3097::AID-CNCR2820741206>3.0.CO;2-P","article-title":"Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer","volume":"74","author":"Tanaka","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib65","first-page":"129","article-title":"Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma","volume":"28","author":"Chi","year":"2005","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib66","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-05-1485","article-title":"Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma","volume":"12","author":"Duval","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib67","first-page":"513","article-title":"Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer","volume":"35","author":"Fujiwara","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer","volume":"24","author":"van Schalkwyk","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib69","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","article-title":"Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020","volume":"24","author":"Cornett","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.23168","article-title":"Isolated limb perfusion with the\u00a0tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma","volume":"107","author":"Papadia","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00002371-199507000-00003","article-title":"Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer","volume":"18","author":"Hennemann","year":"1995","journal-title":"J\u00a0Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0959-8049(05)80028-0","article-title":"Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases","volume":"30A","author":"Keilholz","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib73","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s004320050166","article-title":"Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I\/II clinical trials","volume":"124","author":"Zeng","year":"1998","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01212721","article-title":"Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results","volume":"119","author":"Zeng","year":"1993","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib75","first-page":"545","article-title":"Hepatic arterial administration of activated leukocytes in patients with liver metastases","volume":"17","author":"Melichar","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.canlet.2015.03.024","article-title":"Awakening the immune system with radiation: optimal dose and fractionation","volume":"368","author":"Gandhi","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib78","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00199131","article-title":"Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report","volume":"22","author":"Bakker","year":"1986","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib80","first-page":"391","article-title":"Intrapleural BCG in postsurgical stage I non-small cell lung cancer","volume":"9","author":"Macchiarini","year":"1989","journal-title":"Anticancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00000658-198509000-00010","article-title":"A\u00a0randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung. The Lung Cancel Study Group","volume":"202","author":"Holmes","year":"1985","journal-title":"Ann Surg"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib82","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00205383","article-title":"Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study","volume":"13","author":"Roeslin","year":"1982","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib83","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-5223(19)39476-0","article-title":"Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer","volume":"81","author":"McKneally","year":"1981","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib84","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thx.35.10.781","article-title":"Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma","volume":"35","author":"Jansen","year":"1980","journal-title":"Thorax"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib85","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","article-title":"Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"83","author":"Astoul","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib86","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1378\/chest.103.1.209","article-title":"Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion","volume":"103","author":"Astoul","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0169-5002(00)00192-6","article-title":"Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients","volume":"31","author":"Castagneto","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib88","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"Goey","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib89","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1002\/1097-0142(19930615)71:12<4067::AID-CNCR2820711243>3.0.CO;2-D","article-title":"Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions","volume":"71","author":"Viallat","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib90","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/thx.35.11.856","article-title":"Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions","volume":"35","author":"Millar","year":"1980","journal-title":"Thorax"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib91","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0022-5223(19)38690-8","article-title":"Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group","volume":"89","year":"1985","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib92","first-page":"1413","article-title":"Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients","volume":"45","author":"Yasumoto","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib93","first-page":"269","article-title":"Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection","volume":"39","author":"Lee","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib94","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1378\/chest.121.6.1921","article-title":"Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study","volume":"121","author":"Monnet","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib95","first-page":"5","article-title":"131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer","volume":"21","author":"Yu","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-004-1497-5","article-title":"Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma","volume":"72","author":"Boiardi","year":"2005","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib97","first-page":"5952s","article-title":"Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors","volume":"55","author":"Riva","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib98","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01052668","article-title":"Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2\u2013a preliminary report","volume":"24","author":"Bigner","year":"1995","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib99","first-page":"963","article-title":"Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results","volume":"2","author":"Brown","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib100","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1096-911X(20001201)35:6<716::AID-MPO51>3.0.CO;2-0","article-title":"Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8","volume":"35","author":"Kramer","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib101","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.3171\/foc.2006.20.4.9","article-title":"Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies","volume":"20","author":"Sampson","year":"2006","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib102","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","article-title":"Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8","volume":"25","author":"Kramer","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1040-8428(01)00122-6","article-title":"Adoptive cellular immunotherapy for the treatment of malignant gliomas","volume":"39","author":"Hayes","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib104","first-page":"175","article-title":"Intratumoral LAK cell and interleukin-2 therapy of human gliomas","volume":"70","author":"Barba","year":"1989","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib105","first-page":"331","article-title":"Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells","volume":"4","author":"Blancher","year":"1993","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01533386","article-title":"Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients","volume":"39","author":"Boiardi","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00177476","article-title":"Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors","volume":"27","author":"Sankhla","year":"1996","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib108","first-page":"189","article-title":"Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial","volume":"4","author":"Rosener","year":"1993","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF01997785","article-title":"Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules","volume":"17","author":"Salmaggi","year":"1996","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib110","first-page":"4027","article-title":"Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma","volume":"26","author":"Oshiro","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib111","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-05-0120","article-title":"Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I\/II trial","volume":"11","author":"Yamanaka","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib112","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00177901","article-title":"Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A phase 1 (toxicity) study","volume":"2","author":"Steinbok","year":"1984","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib113","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bjc.1993.349","article-title":"Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody","volume":"68","author":"Hird","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib114","first-page":"746","article-title":"Anti-chelate antibodies\u00a0after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy","volume":"36","author":"Kosmas","year":"1995","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib115","first-page":"953","article-title":"Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity","volume":"5","author":"Rosenblum","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib116","first-page":"2806","article-title":"A\u00a0Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer","volume":"8","author":"Alvarez","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib117","first-page":"508","article-title":"Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer","volume":"22","author":"Oei","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib118","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0090-8258(92)90302-Y","article-title":"Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125","volume":"45","author":"Muto","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib119","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/172460089300800310","article-title":"Radioimmunotherapy of gastrointestinal cancer and glioblastomas","volume":"8","author":"Riva","year":"1993","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib120","first-page":"3249s","article-title":"A\u00a0phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma","volume":"5","author":"Mahe","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib121","first-page":"586","article-title":"A\u00a0phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response","volume":"82","author":"Jacobs","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib122","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/gyno.1996.4577","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I\/II study","volume":"65","author":"Alvarez","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib123","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2\u2014a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib124","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/1097-0142(19940201)73:3+<1067::AID-CNCR2820731346>3.0.CO;2-#","article-title":"Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer","volume":"73","author":"Maraveyas","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib125","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/ijc.23725","article-title":"Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer","volume":"123","author":"Oei","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib126","first-page":"305","article-title":"Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study","volume":"16","author":"Meredith","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib127","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/jnci\/87.19.1463","article-title":"Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody","volume":"87","author":"Canevari","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib128","first-page":"196","article-title":"Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study","volume":"35","author":"Wright","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib129","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cam4.196","article-title":"Intraperitoneal injection of in\u00a0vitro expanded V\u03b39V\u03b42 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer","volume":"3","author":"Wada","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/scd.1.1995.4.423","article-title":"Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions","volume":"4","author":"Canevari","year":"1995","journal-title":"J\u00a0Hematother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib131","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00262-011-1128-x","article-title":"Immunotherapy with IL-10- and IFN-gamma-producing CD4 effector cells modulate \u201cnatural\u201d and \u201cinducible\u201d CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer","volume":"61","author":"Dobrzanski","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib132","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ijc.2910600405","article-title":"Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes","volume":"60","author":"Lamers","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib133","first-page":"78","article-title":"Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study","volume":"7","author":"Bolhuis","year":"1992","journal-title":"Int J Cancer Suppl"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib134","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib135","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.4161\/hv.26065","article-title":"The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting","volume":"9","author":"Atanackovic","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib136","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-14-148","article-title":"Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab","volume":"14","author":"Goere","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib137","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000324667","article-title":"Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I\/II trial","volume":"34","author":"Strohlein","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib138","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1145>3.0.CO;2-I","article-title":"Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p","volume":"92","author":"van Zanten-Przybysz","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib139","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COC.0b013e3180684181","article-title":"Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma","volume":"31","author":"Hesdorffer","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib140","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3748\/wjg.v8.i6.1019","article-title":"Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection","volume":"8","author":"Fu","year":"2002","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib141","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000055374","article-title":"Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study","volume":"61","author":"Sartori","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib142","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0936-6555(05)80188-8","article-title":"Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement","volume":"6","author":"Frasci","year":"1994","journal-title":"Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002371-199401000-00008","article-title":"Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factor","volume":"15","author":"Toner","year":"1994","journal-title":"J\u00a0Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib144","first-page":"2268","article-title":"Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma","volume":"6","author":"Freedman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00002371-199410000-00004","article-title":"Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial","volume":"16","author":"Freedman","year":"1994","journal-title":"J\u00a0Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib146","first-page":"6302","article-title":"Phase I trial of intraperitoneal recombinant interleukin-2\/lymphokine-activated killer cells in patients with ovarian cancer","volume":"50","author":"Stewart","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib147","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/jir.1995.15.467","article-title":"Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem","volume":"15","author":"Lygidakis","year":"1995","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib148","first-page":"543","article-title":"Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study","volume":"15","author":"Lygidakis","year":"1995","journal-title":"Anticancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib149","first-page":"1685","article-title":"Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study","volume":"48","author":"Lygidakis","year":"2001","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib150","first-page":"155","article-title":"Resection versus resection combined with adjuvant pre- and post-operative chemotherapy\u2013immunotherapy for metastatic colorectal liver cancer. A new look at an old problem","volume":"42","author":"Lygidakis","year":"1995","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib151","first-page":"129","article-title":"Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma","volume":"28","author":"Chi","year":"2005","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib152","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00002371-199507000-00003","article-title":"Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer","volume":"18","author":"Hennemann","year":"1995","journal-title":"J\u00a0Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib153","first-page":"545","article-title":"Hepatic arterial administration of activated leukocytes in patients with liver metastases","volume":"17","author":"Melichar","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib154","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0959-8049(94)00522-7","article-title":"Biological response to intrahepatic adoptive immunotherapy with autologous interferon activated macrophages","volume":"31A","author":"Hennemann","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib156","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1748-717X-8-239","article-title":"A\u00a0phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma","volume":"8","author":"Abei","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib157","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s004320050166","article-title":"Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I\/II clinical trials","volume":"124","author":"Zeng","year":"1998","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib158","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01212721","article-title":"Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results","volume":"119","author":"Zeng","year":"1993","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib159","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0959-8049(05)80028-0","article-title":"Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases","volume":"30A","author":"Keilholz","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","article-title":"Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study","volume":"64","author":"Danielli","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib161","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00262-011-1134-z","article-title":"Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen","volume":"61","author":"Berinstein","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib162","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/hum.2005.16.35","article-title":"Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy","volume":"16","author":"Heinzerling","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib163","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.cgt.7701064","article-title":"Intratumoral injection of IL-12 plasmid DNA\u2013results of a phase I\/IB clinical trial","volume":"14","author":"Mahvi","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib164","first-page":"3861","article-title":"Cancer immunotherapy by intratumoral injection of alpha-gal glycolipids","volume":"32","author":"Whalen","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00005537-200503000-00002","article-title":"Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside","volume":"115","author":"O'Malley","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib166","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.cgt.7700441","article-title":"Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels","volume":"9","author":"Rochlitz","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib167","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/cncr.20653","article-title":"Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide\/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma","volume":"101","author":"Galanis","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib168","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib169","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/00000658-200212000-00013","article-title":"Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study","volume":"236","author":"Lygidakis","year":"2002","journal-title":"Ann Surg"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib170","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/mt.2010.52","article-title":"Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas","volume":"18","author":"Dummer","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib171","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma","volume":"64","author":"Aguilar","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib172","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib173","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CMR.0b013e3282f702cf","article-title":"Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate","volume":"18","author":"Hofbauer","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib174","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/hum.2006.17.239","article-title":"Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors","volume":"17","author":"Kaufman","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib175","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2014.243","article-title":"Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients","volume":"23","author":"Cripe","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib176","first-page":"1291","article-title":"Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer","volume":"166","author":"Gomella","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib177","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.cgt.7700568","article-title":"A\u00a0phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma","volume":"10","author":"Khorana","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib178","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.gt.3301928","article-title":"Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients","volume":"10","author":"Griscelli","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib179","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1172\/JCI24624","article-title":"Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma","volume":"115","author":"Kaufman","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib180","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/1097-0142(19821201)50:11<2295::AID-CNCR2820501113>3.0.CO;2-4","article-title":"Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck","volume":"50","author":"Vogl","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib181","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1054\/bjoc.2000.1599","article-title":"The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients","volume":"84","author":"Gochi","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib182","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/1097-0142(19941215)74:12<3097::AID-CNCR2820741206>3.0.CO;2-P","article-title":"Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer","volume":"74","author":"Tanaka","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib183","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jso.2930280215","article-title":"Adjuvant Corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx","volume":"28","author":"Neifeld","year":"1985","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib184","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/BF02258309","article-title":"Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen","volume":"43","author":"Amano","year":"2000","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib185","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-05-1485","article-title":"Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma","volume":"12","author":"Duval","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib186","first-page":"513","article-title":"Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer","volume":"35","author":"Fujiwara","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib187","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent\u00a0head and neck cancer","volume":"24","author":"van Schalkwyk","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib188","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1097-0142(20001215)89:12<2646::AID-CNCR18>3.0.CO;2-A","article-title":"Intratumoral injection of dendritic cells derived in\u00a0vitro in patients with metastatic cancer","volume":"89","author":"Triozzi","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib189","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2005.06.005","article-title":"Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4\/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial","volume":"23","author":"Timar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib190","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-015-1691-7","article-title":"Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients","volume":"64","author":"Khammari","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib191","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01878153","article-title":"The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages","volume":"7","author":"Takeda","year":"1993","journal-title":"Biotherapy"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib192","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/cgt.2009.9","article-title":"Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients","volume":"16","author":"Victora","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib193","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2249.2007.03521.x","article-title":"Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes","volume":"150","author":"Audia","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.amjsurg.2016.06.008_bib194","first-page":"459","article-title":"Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities","volume":"92","author":"Ariyan","year":"1982","journal-title":"Surgery"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961016303452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961016303452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:12:43Z","timestamp":1762081963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961016303452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":194,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0002961016303452"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2016.06.008","relation":{},"ISSN":["0002-9610"],"issn-type":[{"type":"print","value":"0002-9610"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical immune interventions for solid malignancies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2016.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}